Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer

INTRODUCTION: Triple-negative breast cancer (TNBC) is negative for hormone receptors and human epidermal growth factor receptor 2 (HER2). In stage I TNBC, adjuvant therapy or follow-up are performed according to risk factors, but clinical trial data is scarce. In recent years, it has been reported t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanomachi, Tomomi, Okuma, Hitomi Sumiyoshi, Kitadai, Rui, Kawachi, Asuka, Yazaki, Shu, Tokura, Momoko, Arakaki, Motoko, Saito, Ayumi, Kita, Shosuke, Yamamoto, Kasumi, Maejima, Aiko, Kojima, Yuki, Nishikawa, Tadaaki, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Fujiwara, Yasuhiro, Sugino, Hirokazu, Shiino, Sho, Suto, Akihiko, Yoshida, Masayuki, Yonemori, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083471/
https://www.ncbi.nlm.nih.gov/pubmed/37051545
http://dx.doi.org/10.3389/fonc.2023.1157789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083471/
https://www.ncbi.nlm.nih.gov/pubmed/37051545
http://dx.doi.org/10.3389/fonc.2023.1157789

Ejemplares similares